120 related articles for article (PubMed ID: 31246148)
21. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.
Bruno A; Labreche K; Daniau M; Boisselier B; Gauchotte G; Royer-Perron L; Rahimian A; Lemoine F; de la Grange P; Guégan J; Bielle F; Polivka M; Adam C; Meyronet D; Figarella-Branger D; Villa C; Chrétien F; Eimer S; Davi F; Rousseau A; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K; Alentorn A
Neuro Oncol; 2018 Jul; 20(8):1092-1100. PubMed ID: 29432597
[TBL] [Abstract][Full Text] [Related]
23. No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients.
Martini F; Dolcetti R; Ferreri AJ; Ponzoni M; Fumagalli L; Reni M; Terreni MR; Mariuzzi L; Tognon M
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1819-20. PubMed ID: 15533914
[No Abstract] [Full Text] [Related]
24. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
PLoS One; 2020; 15(2):e0229577. PubMed ID: 32101576
[TBL] [Abstract][Full Text] [Related]
25. Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
Preusser M; Woehrer A; Koperek O; Rottenfusser A; Dieckmann K; Gatterbauer B; Roessler K; Slavc I; Jaeger U; Streubel B; Hainfellner JA; Chott A
Pathology; 2010; 42(6):547-52. PubMed ID: 20854073
[TBL] [Abstract][Full Text] [Related]
26. Differential gene expression in central nervous system lymphoma.
Rubenstein JL; Shen A; Batchelor TT; Kadoch C; Treseler P; Shuman MA
Blood; 2009 Jan; 113(1):266-7; author reply 267-8. PubMed ID: 19122120
[No Abstract] [Full Text] [Related]
27. AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies (review).
Silvestris N; Crucitta E; Lorusso V; Gamucci T; De Lena M
Int J Oncol; 2002 Mar; 20(3):611-5. PubMed ID: 11836577
[TBL] [Abstract][Full Text] [Related]
28. A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus.
Sharma MC; Gupta RK; Kaushal S; Suri V; Sarkar C; Singh M; Kale SS; Sahoo RK; Kumar L; Raina V
Indian J Med Res; 2016 May; 143(5):605-15. PubMed ID: 27488004
[TBL] [Abstract][Full Text] [Related]
29. Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51.
McPhail ER; Law ME; Decker PA; O'Neill BP
Br J Haematol; 2011 Jul; 154(1):146-50. PubMed ID: 21275973
[No Abstract] [Full Text] [Related]
30. Late relapse of primary central nervous system lymphoma.
Yamanaka R; Morii K; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tsukamoto Y; Ogura R; Natsumeda M; Aoki H; Akiyama K; Saitoh T; Tamura T; Hondoh H; Kawaguchi A; Takahashi H; Fujii Y
Leuk Lymphoma; 2017 Feb; 58(2):475-477. PubMed ID: 27397141
[No Abstract] [Full Text] [Related]
31. Concurrent presence of cryptococcal meningitis and primary central nervous system (CNS) non-Hodgkin's lymphoma in a non-HIV patient.
Gupta K; Radotra BD; Gupta V; Wanchu A
Neuropathol Appl Neurobiol; 2008 Apr; 34(2):241-4. PubMed ID: 17961135
[No Abstract] [Full Text] [Related]
32. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.
Kaulen LD; Galluzzo D; Hui P; Barbiero F; Karschnia P; Huttner A; Fulbright R; Baehring JM
J Neurooncol; 2019 Aug; 144(1):107-115. PubMed ID: 31190317
[TBL] [Abstract][Full Text] [Related]
33. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
34. Treatment of primary central nervous system lymphoma.
Ekenel M; DeAngelis LM
Curr Neurol Neurosci Rep; 2007 May; 7(3):191-9. PubMed ID: 17488584
[TBL] [Abstract][Full Text] [Related]
35. Primary central nervous system lymphoma: curable without toxicity?
DeAngelis LM
Cancer J Sci Am; 1996; 2(3):137-9. PubMed ID: 9166513
[No Abstract] [Full Text] [Related]
36. Central nervous system lymphoma newly developed 12 years after remission of an ocular adnexal lymphoma.
Morikawa K; Tsuji T; Yamasaki H; Toyozumi Y; Arima N; Ohshima K; Tsuda H
Acta Haematol; 2013; 130(4):247-50. PubMed ID: 23860499
[TBL] [Abstract][Full Text] [Related]
37. Primary Central Nervous System Lymphoma.
Dong YH; Teng ZJ; Hu M; Wei C; Chen YM; Zhao HF; Zhang SQ; Lyu PY
Chin Med J (Engl); 2016 Mar; 129(5):609-11. PubMed ID: 26904999
[No Abstract] [Full Text] [Related]
38. Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.
Lim DH; Kim WS; Kim SJ; Yoo HY; Ko YH
Anticancer Res; 2015 Jun; 35(6):3333-40. PubMed ID: 26026093
[TBL] [Abstract][Full Text] [Related]
39. Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Herrlinger U; Hebart H; Kanz L; Dichgans J; Weller M
J Neurol; 2005 Nov; 252(11):1409-10. PubMed ID: 15895304
[No Abstract] [Full Text] [Related]
40. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
